Physician profile
Gregory Rasp
NPI 1609821842
$3,996.55
in general payments reported to CMS, 2019-2025
55 companies · $812 in 2025
The $812 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $191 · 2021: $168 · 2022: $411 · 2023: $864 · 2024: $809 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $363.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $311.53 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Progenics Pharmaceuticals, INC. | $242.23 | 2023-2024 | Pylarify |
| Eisai INC. | $236.42 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $182.98 | 2023-2025 | Prolaris, Myrisk |
| Celgene Corporation | $179.28 | 2022-2025 | Opdualag, Opdivo, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $174.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $154.85 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $131.27 | 2019-2025 | Erleada, Balversa, Rybrevant |
| Lilly USA, LLC | $117.63 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $116.10 | 2019-2024 | Xtandi, Padcev |
| Jazz Pharmaceuticals INC. | $114.42 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $100.58 | 2020-2023 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $81.29 | 2019-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $80.41 | 2019-2025 | Opdualag, Opdivo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Rasp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.